Environmental Acoustics is a professional course that educates students majoring in Acoustics.Affected by practical equipment and other factors,the teaching effect of knowledge points relevant to subjective auditory p...Environmental Acoustics is a professional course that educates students majoring in Acoustics.Affected by practical equipment and other factors,the teaching effect of knowledge points relevant to subjective auditory perception contained in the course is poor.Taking the course of Spatial Hearing and 3D Stereo as an example,this study develops a virtual simulation experiment system for the topic of subjective hearing perception in order to carry out the reform and practice of immersive teaching.Combined with the virtual simulation experiment project with high sense of presence,students are supported by the actual auditory perception effect in the whole learning process and have achieved good learning effect.展开更多
Background:TP53 mutations and homologous recombination deficiency(HRD)occur frequently in breast cancer.However,the characteristics of TP53 pathogenic mutations in breast cancer patients with/without HRD are not clear...Background:TP53 mutations and homologous recombination deficiency(HRD)occur frequently in breast cancer.However,the characteristics of TP53 pathogenic mutations in breast cancer patients with/without HRD are not clear.Methods:Clinical next-generation sequencing(NGS)of both tumor and paired blood DNA from 119 breast cancer patients(BRCA-119 cohort)was performed with a 520-gene panel.Mutations,tumor mutation burden(TMB),and genomic HRD scores were assessed from NGS data.NGS data from 47 breast cancer patients in the HRD test cohort were analyzed for further verification.Results:All TP53 pathogenic mutations in patients had somatic origin,which was associated with the protein expression of estrogen receptor and progestogen receptor.Compared to patients without TP53 pathologic mutations,patients with TP53 pathologic mutations had higher levels of HRD scores and different genomic alterations.The frequency of TP53 pathologic mutation was higher in the HRDhigh group(HRD score≥42)relative to that in the HRD-low group(HRD score<42).TP53 has different mutational characteristics between the HRD-low and HRD-high groups.TP53-specific mutation subgroups had diverse genomic features and TMB.Notably,TP53 pathogenic mutations predicted the HRD status of breast cancer patients with an area under the curve(AUC)of 0.61.TP53-specific mutations,namely HRD-low mutation,HRD-high mutation,and HRD common mutation,predicted the HRD status of breast cancer patients with AUC values of 0.32,0.72,and 0.58,respectively.Interestingly,TP53 HRD-high mutation and HRD common mutation combinations showed the highest AUC values(0.80)in predicting HRD status.Conclusions:TP53-specific mutation combinations predict the HRD status of patients,indicating that TP53 pathogenic mutations could serve as a potential biomarker for poly-ADP-ribose polymerase(PARP)inhibitors in breast cancer patients.展开更多
基金This research was supported by the Key Teaching Reform Project of Northwestern Polytechnical University-Practical Teaching Reform of Environmental Acoustics Course Group Supported by Virtual Auditory Perception Experiment Project(Project Number:2021JGZ04).
文摘Environmental Acoustics is a professional course that educates students majoring in Acoustics.Affected by practical equipment and other factors,the teaching effect of knowledge points relevant to subjective auditory perception contained in the course is poor.Taking the course of Spatial Hearing and 3D Stereo as an example,this study develops a virtual simulation experiment system for the topic of subjective hearing perception in order to carry out the reform and practice of immersive teaching.Combined with the virtual simulation experiment project with high sense of presence,students are supported by the actual auditory perception effect in the whole learning process and have achieved good learning effect.
基金funding from the National Natural Science Foundation of China(Grants No.82203435,82203703,82203141,and 82102865)Guangdong Basic and Applied Basic Research Foundation(Grant No.2021A1515111138)+1 种基金Guangzhou Science and Technology Plan Project Support(Grant No.2023A04J2103)the China Postdoctoral Science Foundation(Grants No.2022M713576 and 2022T150757).
文摘Background:TP53 mutations and homologous recombination deficiency(HRD)occur frequently in breast cancer.However,the characteristics of TP53 pathogenic mutations in breast cancer patients with/without HRD are not clear.Methods:Clinical next-generation sequencing(NGS)of both tumor and paired blood DNA from 119 breast cancer patients(BRCA-119 cohort)was performed with a 520-gene panel.Mutations,tumor mutation burden(TMB),and genomic HRD scores were assessed from NGS data.NGS data from 47 breast cancer patients in the HRD test cohort were analyzed for further verification.Results:All TP53 pathogenic mutations in patients had somatic origin,which was associated with the protein expression of estrogen receptor and progestogen receptor.Compared to patients without TP53 pathologic mutations,patients with TP53 pathologic mutations had higher levels of HRD scores and different genomic alterations.The frequency of TP53 pathologic mutation was higher in the HRDhigh group(HRD score≥42)relative to that in the HRD-low group(HRD score<42).TP53 has different mutational characteristics between the HRD-low and HRD-high groups.TP53-specific mutation subgroups had diverse genomic features and TMB.Notably,TP53 pathogenic mutations predicted the HRD status of breast cancer patients with an area under the curve(AUC)of 0.61.TP53-specific mutations,namely HRD-low mutation,HRD-high mutation,and HRD common mutation,predicted the HRD status of breast cancer patients with AUC values of 0.32,0.72,and 0.58,respectively.Interestingly,TP53 HRD-high mutation and HRD common mutation combinations showed the highest AUC values(0.80)in predicting HRD status.Conclusions:TP53-specific mutation combinations predict the HRD status of patients,indicating that TP53 pathogenic mutations could serve as a potential biomarker for poly-ADP-ribose polymerase(PARP)inhibitors in breast cancer patients.